IDH2 and acute myeloid leukemia: Moreover, a multicenter, open-label, randomized, phase III study IDHENTIFY is currently ongoing worldwide, and recruiting elderly subjects (≥60 years) with IDH2-mutated advanced AML, to compare enasidenib treatment to conventional care regimens (NCT02577406).